AbbVie Elahere (mirvetuximab soravtansine) by Quarter

Name: AbbVie Elahere (mirvetuximab soravtansine) by Quarter (ABBV)
Creator: AbbVie

Elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M) ($M)

Quarterly Annual

AbbVie Elahere (mirvetuximab soravtansine): $211M in Q2 2026, up 32.7% from a year earlier. That is the highest of the 10 quarters on record here.

Latest, Q2 2026

211

Period ended Jun 30, 2026

Change on a year earlier

+32.7%

159 in Q2 2025

History

10 quarters

Since Q1 2024

Sources

Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-03) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	211	+32.7%	Form 10-Q (filed 2026-08-03) ↗
Q1 2026	Mar 31, 2026	198	+10.6%	Form 10-Q (filed 2026-05-08) ↗
Q4 2025	Dec 31, 2025	182	+23.0%	Form 10-K (filed 2026-02-20) ↗
Q3 2025	Sep 30, 2025	170	+22.3%	Form 10-Q (filed 2025-11-04) ↗
Q2 2025	Jun 30, 2025	159	+24.2%	Form 10-Q (filed 2026-08-03) ↗
Q1 2025	Mar 31, 2025	179	+179.7%	Form 10-Q (filed 2026-05-08) ↗
Q4 2024	Dec 31, 2024	148	–	Form 10-K (filed 2026-02-20) ↗
Q3 2024	Sep 30, 2024	139	–	Form 10-Q (filed 2025-11-04) ↗
Q2 2024	Jun 30, 2024	128	–	Form 10-Q (filed 2025-08-04) ↗
Q1 2024	Mar 31, 2024	64	–	Form 10-Q (filed 2025-05-09) ↗

Breakdown

What makes up elahere (mirvetuximab soravtansine)

Cite this data

StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere-ww

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.